In the process of building relationships between Japanese pharmaceuticals, biotech companies, and academia since our establishment in 2016, we obtained more suggestions than expected and were strongly convinced of the existence of “unutilized innovative drug seeds in Japan.”
As a result of such activities, we assessed a lot of drug seeds, according to the following selection criteria, and decided to acquire the following pipelines.

Selection criteria of drug seeds

  1. Since the therapeutic area and development stage conform with our strategy, we can utilize our expertise.
  2. There is a great potential to solve high unmet medical needs.
  3. Adequate return on our investment is expected.

Our pipeline

Code Indication Mechanism Discovery
non-clinical study
[ GLP ]
Ph1 Ph2
[ POC ]
CP1050 Autoimmune diseases such as multiple sclerosis (MS) S1P receptor modulator Ongoing
CP2090 Fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH) LPA1 selective antagonist Ongoing
You can scroll this table horizontally.